• The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022. • Cancer treatment services as a segment should reach nearly $43.9 billion in 2017 and $83.6 billion by 2022, at a CAGR of 13.8% through 2022. • Diagnosis and detection services as a segment should reach nearly $2.9 billion in 2017 and $5.8 billion by 2022, at a CAGR of 15.0% through 2022.
Chapter 1: Introduction
Study Goals and Objectives The Chinese cancer intervention market is big, fast-growing, and dominated by drug and equipment suppliers from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions and which are looking for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehensive understanding of the recent advances and trends in the cancer intervention industry and market in China. Toward this end, this report will cover the market for products for different types of cancer to 2022. The report provides a comprehensive discussion of cancer intervention applications, industry structure, marketing and distribution, partnerships, and companies. The report is designed to aid companies in their strategic planning efforts for accessing cancer intervention industry opportunities in the Chinese market.
Reasons for Doing This Study This study will help pharmaceutical companies, medical equipment suppliers, medical institutions, and drug wholesalers and distributors gain an in-depth understanding on the Chinese cancer intervention market.
Scope of Report The scope of the report includes cancer intervention applications, industries, markets, and companies in China. The markets for cancer intervention are given for the years 2016, 2017 and 2022. The Chinese cancer intervention market includes two major segments: cancer treatment and cancer diagnosis and detection. Each major segment will be further divided and discussed by technology, drug type, end user, etc. In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities), and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai and others.
Information Sources Information sources for this report include experts, executives, professors, and officials in the Chinese cancer intervention industry. They are from pharmaceutical companies, associations and governmental departments. Information sources for the study also include online research, patent literature, technical journals, trade magazines, governmental data, public speeches, and conference papers.
Methodology Both primary and secondary research methodologies were used in preparing this study. Estimates of current market demand are made for 2016 and are projected for the next five years from 2017 through 2022. Projections are made in terms of constant U.S. dollars (2016), unadjusted for inflation. Growth is presented in terms of a compound average annual growth rate (CAGR). Sales values are measured at end consumer level; reasons are discussed in the report.
Geographic Breakdown In this report, the geographic regions considered for market analysis include, and only include: North China • Beijing • Hebei • Shanxi • Tianjin • Inner Mongolia East China • Shanghai • Shandong • Zhejiang • Jiangsu • Fujian • Anhui South China • Guangdong • Guangxi • Hainan Middle China • Hubei • Henan • Hunan • Jiangxi Northwest China • Shaanxi • Xinjiang • Gansu • Qinghai • Ningxia
Southwest China • Sichuan • Chongqing • Yunnan • Guizhou • Tibet Northeast China • Liaoning • Heilongjiang • Jilin
Our reports have been used by over 10K customers, including:
195 pages •
By BioInformant Worldwide, L.L.C.
• Sep 2018
EXECUTIVE SUMMARY CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications. What...
Scope of the Report The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1...
INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...
Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Cervical cancer diagnostic market in Asian region is growing and expected to cross over USD 1 Billion by 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally...
Scope of the Report The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio. Moreover,...
71 pages •
By Asia Market Information & Development Company
• May 2018
This study focuses on China’s Lymphoma Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....